Advances in quantitative structure-activity relationship models of anti-Alzheimer's agents

Expert Opinion on Drug Discovery

Volumn 9, Issue 6, 2014, Pages 697-723

  Ambure, Pravin ^a   Roy, Kunal ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Alzheimer's disease; Cheminformatics; Chemometrics; Quantitative structure activity relationship

Indexed keywords

AMYLOID; CHOLINERGIC RECEPTOR STIMULATING AGENT; DONEPEZIL; FLORBETAPIR F 18; FLUTEMETAMOL F 18; GALANTAMINE; MEMANTINE; RIVASTIGMINE; TACRINE; TAU PROTEIN; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; COMPUTER MODEL; DIAGNOSTIC PROCEDURE; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG DESIGN; DRUG TARGETING; HISTORY; HUMAN; PALLIATIVE THERAPY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SYMPTOM; VALIDATION STUDY; COMPUTER SIMULATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; COMPUTER SIMULATION; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84901272158     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.909404     Document Type: Review

References (124)

1. Alzheimer's Disease Education and Referral Center. About Alzheimer's Disease: Alzheimer's Basic. Available from: Http://www.nia.nih.gov/alzheimers/ topics/alzheimers-basics [Last accessed 10 January 2014]
2. Maurer K, Volk S, Gerbaldo H, Auguste D. Alzheimer's disease. Lancet 1997;349(9064):1546-9
3. Minati L, Edginton T, Bruzzone MG, Giaccone G. Reviews: Current concepts in alzheimer's disease: A multidisciplinary review. Am J Alzheimers Dis Other Demen 2009;24(2):95-121
4. Wimo A, Prince MJ. World alzheimer report 2010: The global economic impact of dementia. Alzheimer's Disease International; 2010. Available from: Http://www.alz.co.uk/ research/world-report-2010
5. 2009 Progress Report on Alzheimer's Disease: Translating New Knowledge National Institute on Aging, National Institutes of Health, US Department of Health and Human Services, Publication no 10-7500,November 2010
6. Alzheimer's Disease Education & Referral (ADEAR) Center. Alzheimer's disease fact sheet. US Department of Health and Human Services, National Institutes of Health NIH Publication No 11-6423 July 2011 2011
7. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry 1999;66(2):137-47 (Pubitemid 29103513
8. Lee VMY, Brunden KR, Hutton M, Trojanowski JQ. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med 2011;1(1):a006437
9. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12:383-8
10. Mendez MF. The accurate diagnosis of early-onset dementia. Int J Psychiatry Med 2006;36(4):401-12 (Pubitemid 47105277
11. Coimbra A, Williams DS, Hostetler ED. The role of MRI and PET/SPECT in Alzheimers disease. Curr Top Med Chem 2006;6(6):629-47
12. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002;297(5580):353-6 (Pubitemid 34790756
13. Ono M, Saji H. SPECT imaging agents for detecting cerebral b-Amyloid plaques. Int J Mol Imaging 2011;2011:543267
14. Thies W, Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimers Dement 2011;7(2):208
15. Roy K, Mitra I. On various metrics used for validation of predictive QSAR models with applications in virtual screening and focused library design. Comb Chem High Throughput Screen 2011;14(6):450-74
16. Basak SC, Gute BD, Grunwald GD. Use of topostructural, topochemical, and geometric parameters in the prediction of vapor pressure: A hierarchical QSAR approach. J Chem Inf Comput Sci 1997;37(4):651-5 (Pubitemid 127603577
17. Verma J, Khedkar VM, Coutinho EC. 3D-QSAR in drug design-A review. Curr Top Med Chem 2010;10(1):95-115
18. Rosenbaum L, Dorr A, Bauer MR, et al. Inferring multi-Target QSAR models with taxonomy-based multi-Task learning. J Cheminform 2013;5(1):33
19. Prado-Prado F, Garcia-Mera X, Escobar M, et al. 3D MI-DRAGON: New model for the reconstruction of US FDA drug-Target network and theoretical- experimental studies of inhibitors of rasagiline derivatives for AChE. Curr Top Med Chem 2012;12(16):1843-65
20. Speck-Planche A, V Kleandrova V, Luan F, Cordeiro NDS. Multi-Target inhibitors for proteins associated with Alzheimer: In silico discovery using fragment-based descriptors. Curr Alzheimer Res 2013;10(2):117-24
21. Luan F, Cordeiro M, Alonso N, et al. TOPS-MODE model of multiplexing neuroprotective effects of drugs and experimental-Theoretic study of new 1, 3-rasagiline derivatives potentially useful in neurodegenerative diseases. Bioorg Med Chem 2013;21(7):1870-9
22. Ma XH, Shi Z, Tan C, et al. In-silico approaches to multi-Target drug discovery. Pharm Res 2010;27(5):739-49
23. Pratim Roy P, Paul S, Mitra I, Roy K. On two novel parameters for validation of predictive QSAR models. Molecules 2009;14(5):1660-701
24. Roy K, Chakraborty P, Mitra I, et al. Some case studies on application of rm2 metrics for judging quality of quantitative structure-Activity relationship predictions: Emphasis on scaling of response data. J Comput Chem 2013;34(12):1071-82
25. Golbraikh A, Tropsha A. Beware of q2. J Mol Graph Model 2002;20(4):269-76
26. Tropsha A. Best practices for QSAR model development, validation, and exploitation. Mol Inform 2010;29(6-7):476-88
27. Golbraikh A, Muratov EN, Fourches D, Tropsha A. Dataset modelability by QSAR. J Chem Inf Model 2013;54(1):1-4
28. Guha R, Van Drie JH. Structure-Activity landscape index: Identifying and quantifying activity cliffs. J Chem Inf Model 2008;48(3):646-58 (Pubitemid 351535432
29. Seebeck B, Wagener M, Rarey M. From activity cliffs to target-specific scoring models and pharmacophore hypotheses. ChemMedChem 2011;6(9):1630-9
30. Stumpfe D, Hu Y, Dimova D, Bajorath J. Recent progress in understanding activity cliffs and their utility in medicinal chemistry: Miniperspective. J Med Chem 2014;57(1):18-28
31. Hu Y, Stumpfe D, Bajorath J. Advancing the activity cliff concept. F1000Res 2013;2:199
32. Koutsoukas A, Paricharak S, Galloway W, et al. How diverse are diversity assessment methods? A comparative analysis and benchmarking of molecular descriptor space. J Chem Inf Model 2013. [Epub ahead of print]
33. Martin TM, Harten P, Young DM, et al. Does rational selection of training and test sets improve the outcome of QSAR modeling? J Chem Inf Model 2012;52(10):2570-8
34. Dearden JC, Cronin MTD, Kaiser KLE. How not to develop a quantitative structure-Activity or structure-property relationship (QSAR/QSPR). SAR QSAR Environ Res 2009;20(3-4):241-66
35. Cramer RD. The inevitable QSAR renaissance. J Comput Aided Mol Des 2012;26(1):35-8
36. Cherkasov A, Muratov EN, Fourches D, et al. QSAR modeling: Where have you been? Where are you going tö J Med Chem 2014. [Epub ahead of print]
37. Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: An important new target in Alzheimer's disease therapy. Int Psychogeriatr 2002;14(S1):77-91 (Pubitemid 36206092
38. Tong W, Collantes ER, Chen Y, Welsh WJ. A comparative molecular field analysis study of N-benzylpiperidines as acetylcholinesterase inhibitors. J Med Chem 1996;39(2):380-7 (Pubitemid 26041451
39. Recanatini M, Cavalli A, Hansch C. A comparative QSAR analysis of acetylcholinesterase inhibitors currently studied for the treatment of Alzheimer's disease. Chem Biol Interact 1997;105(3):199-228 (Pubitemid 27353309
40. Debord J, N'Diaye P, Bollinger JC, et al. Cholinesterase inhibition by derivatives of 2-Amino-4, 6-dimethylpyridine. J Enzyme Inhib 1997;12(1):13-26 (Pubitemid 27207846
41. Xu R, Sim M-K, Go M-L. Synthesis and pharmacological characterization of Oalkynyloximes of tropinone and Nmethylpiperidinone as muscarinic agonists. J Med Chem 1998;41(17):3220-31 (Pubitemid 28376527
42. Kaur J, Zhang MQ. Molecular modelling and QSAR of reversible acetylcholines-Terase inhibitors. Curr Med Chem 2000;7(3):273-94 (Pubitemid 30396439
43. Nielsen SF, Nielsen EO, Olsen GM, et al. Novel potent ligands for the central nicotinic acetylcholine receptor: Synthesis, receptor binding, and 3D-QSAR analysis. J Med Chem 2000;43(11):2217-26
44. Recanatini M, Cavalli A, Belluti F, et al. SAR of 9-Amino-1, 2, 3, 4-Tetrahydroacridine-based acetylcholinesterase inhibitors: Synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of tacrine analogues. J Med Chem 2000;43(10):2007-18
45. Sippl W, Contreras J-M, Parrot I, et al. Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors. J Comput Aided Mol Des 2001;15(5):395-410 (Pubitemid 32454468
46. Nicolotti O, Pellegrini-Calace M, Altomare C, et al. Ligands of neuronal nicotinic acetylcholine receptor (nAChR): Inferences from the Hansch and 3-D quantitative structure-Activity relationship (QSAR) models. Curr Med Chem 2002;9(1):1-29 (Pubitemid 34436446
47. Nicolotti O, Altomare C, Pellegrini-Calace M, Carotti A. Neuronal nicotinic acetylcholine receptor agonists: Pharmacophores, evolutionary QSAR and 3D-QSAR models. Curr Top Med Chem 2004;4(3):335-60 (Pubitemid 38842573
48. Lin G, Chen G-H, Lu C-P, Yeh S-C. QSARs for peripheral anionic site of butyrylcholinesterase with inhibitions by 4-Acyloxy-biphenyl-4'-N- butylcarbamates. QSAR Comb Sci 2005;24(8):943-52 (Pubitemid 41551506
49. Shen L-L, Liu G-X, Tang Y. Molecular docking and 3D-QSAR studies of 2-substituted 1-indanone derivatives as acetylcholinesterase inhibitors. Acta Pharmacol Sin 2007;28:2053-63 (Pubitemid 350198335
50. Liu A, Guang H, Zhu L, et al. 3D-QSAR analysis of a new type of acetylcholinesterase inhibitors. Sci China C Life Sci 2007;50(6):726-30 (Pubitemid 350172387
51. Zaheer-ul H, Uddin R, Yuan H, et al. Receptor-based modeling and 3D-QSAR for a quantitative production of the butyrylcholinesterase inhibitors based on genetic algorithm. J Chem Inf Model 2008;48(5):1092-103
52. Roy KK, Dixit A, Saxena AK. An investigation of structurally diverse carbamates for acetylcholinesterase (AChE) inhibition using 3D-QSAR analysis. J Mol Graph Model 2008;27(2):197-208
53. Ul-Haq Z, Mahmood U, Jehangir B. Ligand-based 3D-QSAR Studies of Physostigmine Analogues as Acetylcholinesterase Inhibitors. Chem Biol Drug Des 2009;74(6):571-81
54. Asadabadi EB, Abdolmaleki P, Barkooie SMH, et al. A combinatorial feature selection approach to describe the QSAR of dual site inhibitors of acetylcholinesterase. Comput Biol Med 2009;39(12):1089-95
55. Solomon KA, Sundararajan S, Abirami V. QSAR studies on N-Aryl derivative activity towards Alzheimer's disease. Molecules 2009;14(4):1448-55
56. Takahashi J, Hijikuro I, Kihara T, et al. Design, synthesis, evaluation and QSAR analysis of N1-substituted norcymserine derivatives as selective butyrylcholinesterase inhibitors. Bioorg Med Chem Lett 2010;20(5):1718-20
57. Gupta S, Fallarero A, Vainio MJ, et al. Molecular docking guided comparative GFA, G/PLS, SVM and ANN models of structurally diverse dual binding site acetylcholinesterase inhibitors. Mol Inform 2011;30(8):689-706
58. Bitencourt M, Freitas MP, Rittner R. The MIA-QSAR method for the prediction of bioactivities of possible acetylcholinesterase inhibitors. Arch Pharm (Weinheim) 2012;345(9):723-8
59. Yan A, Wang K. Quantitative structure and bioactivity relationship study on human acetylcholinesterase inhibitors. Bioorg Med Chem Lett 2012;22(9):3336-42
60. Ambure P, Kar S, Roy K. Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer's agents. Biosystems 2014;116:10-20
61. Deb PK, Sharma A, Piplani P, Akkinepally RR. Molecular docking and receptor-specific 3D-QSAR studies of acetylcholinesterase inhibitors. Mol Divers 2012;16(4):803-23
62. de Souza SD, de Souza AMT, de Sousa ACC, et al. Hologram QSAR models of 4-[(diethylamino) methyl]-phenol inhibitors of acetyl/ butyrylcholinesterase enzymes as potential anti-Alzheimer agents. Molecules 2012;17(8):9529-39
63. Chitranshi N, Gupta S, Tripathi PK, Seth PK. New molecular scaffolds for the design of Alzheimer's acetylcholinesterase inhibitors identified using ligand-And receptor-based virtual screening. Med Chem Res 2013;22(5):2328-45
64. Debnath B, Gayen S, Basu A, et al. Quantitative structure-Activity relationship study on some benzodiazepine derivatives as anti-Alzheimer agents. J Mol Model 2004;10(5-6):328-34 (Pubitemid 40012061
65. Ravi Keerti A, Ashok Kumar B, Parthasarathy T, Uma V. QSAR studies potent benzodiazepine gamma-secretase inhibitors. Bioorg Med Chem 2005;13(5):1873-8 (Pubitemid 40215275
66. Al-Nadaf A, Sheikha GA, Taha MO. Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads. Bioorg Med Chem 2010;18(9):3088-115
67. Salum LB, Valadares NF. Fragment-guided approach to incorporating structural information into a CoMFA study: BACE-1 as an example. J Comput Aided Mol Des 2010;24(10):803-17
68. Manoharan P, Vijayan RSK, Ghoshal N. Rationalizing fragment based drug discovery for BACE1: Insights from FBQSAR, FB-QSSR, multi objective (MOQSPR) and MIF studies. J Comput Aided Mol Des 2010;24(10):843-64
69. Liu S, Fu R, Cheng X, et al. Exploring the binding of BACE-1 inhibitors using comparative binding energy analysis (COMBINE). BMC Struct Biol 2012;12(1):21
70. Meek AR, Simms GA, Weaver DF. In silico search for an endogenous anti-Alzheimer's molecule-Screening amino acid metabolic pathways. Can J Chem 2012;90(10):865-73
71. Nastase AF, Boyd DB. Simple structurebased approach for predicting the activity of inhibitors of beta-secretase (BACE1) associated with Alzheimer's disease. J Chem Inf Model 2012;52(12):3302-7
72. Manoharan P, Ghoshal N. Rationalizing lead optimization by consensus 2DCoMFA CoMSIA GRIND (3D) QSAR guided fragment hopping in search of beta-secretase inhibitors. Mol Divers 2012;16(3):563-77
73. Bhadoriya KS, Sharma MC, Sharma S, et al. An approach to design potent anti-Alzheimer's agents by 3D-QSAR studies on fused 5, 6-bicyclic heterocycles as beta-secretase modulators using kNNMFA methodology. Arab J Chem 2013; Available from: Http://dx.doi.org/ 10.1016/j.arabjc.2013.02.002
74. Suzuki K, Hamada Y, Nguyen J-T, Kiso Y. Novel BACE1 inhibitors with a non-Acidic heterocycle at the P1' position. Bioorg Med Chem 2013;21(21):6665-73
75. Valasani KR, Hu G, Chaney MO, Yan SS. Structure-based design and synthesis of benzothiazole phosphonate analogues with inhibitors of human ABAD-Amyloid beta for treatment of Alzheimer's disease. Chem Biol Drug Des 2013;81(2):238-49
76. Li Y-P, Weng X, Ning F-X, et al. 3D-QSAR studies of azaoxoisoaporphine, oxoaporphine, and oxoisoaporphine derivatives as anti-AChE and anti-AD agents by the CoMFA method. J Mol Graph Model 2013;41:61-7
77. Huang D, Liu Y, Shi B, et al. Comprehensive 3D-QSAR and binding mode of BACE-1 inhibitors using Rgroup search and molecular docking. J Mol Graph Model 2013;45:65-83
78. Hossain T, Islam MA, Pal R, Saha A. Exploring structural requirement and binding interactions of b-Amyloid cleavage enzyme inhibitors using molecular modeling techniques. Med Chem Res 2013;22(10):4766-74
79. Abu Hammad AM, Taha MO. Pharmacophore modeling, quantitative structure-Activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors. J Chem Inf Model 2009;49(4):978-96
80. Jain P, Jadhav HR. Quantitative structure activity relationship analysis of aminoimidazoles as BACE-I inhibitors. Med Chem Res 2013;22(4):1740-6
81. Ajmani S, Janardhan S, Viswanadhan VN. Toward a general predictive QSAR model for gammasecretase inhibitors. Mol Divers 2013;17:421-34
82. Aplin AE, Gibb GM, Jacobsen JS, et al. In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. J Neurochem 1996;67(2):699-707
83. Martinez A, Alonso M, Castro A, et al. SAR and 3D-QSAR studies on thiadiazolidinone derivatives: Exploration of structural requirements for glycogen synthase kinase 3 inhibitors. J Med Chem 2005;48(23):7103-12 (Pubitemid 41743624
84. Sivaprakasam P, Xie A, Doerksen RJ. Probing the physicochemical and structural requirements for glycogen synthase kinase-3a inhibition: 2D-QSAR for 3-Anilino-4-phenylmaleimides. Bioorg Med Chem 2006;14(24):8210-18 (Pubitemid 44667564
85. Dessalew N, Patel DS, Bharatam PV. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors. J Mol Graph Model 2007;25(6):885-95 (Pubitemid 46216123
86. Lather V, Kristam R, Saini JS, et al. QSAR models for prediction of glycogen synthase kinase-3beta inhibitory activity of indirubin derivatives. QSAR Comb Sci 2008;27(6):718-28
87. Prasanna S, Daga PR, Xie A, Doerksen RJ. Glycogen synthase kinase-3 inhibition by 3-Anilino-4-phenylmaleimides: Insights from 3DQSAR and docking. J Comput Aided Mol Des 2009;23(2):113-27
88. Park HR, Kim MK, Kim DW, et al. 3D QSAR CoMFA Study on Phenylthiazolylhydrazide (PTH) Derivataives as Tau Protein Aggregation Inhibitors. Bull Korean Chem Soc 2010;31(12):3838-41
89. Fang J, Huang D, Zhao W, et al. A new protocol for predicting novel GSK-3b ATP competitive inhibitors. J Chem Inf Model 2011;51(6):1431-8
90. García I, Fall Y, Gomez G, Gonzalez-Diaz H. First computational chemistry multi-Target model for anti-Alzheimer, anti-parasitic, anti-fungi, and anti-bacterial activity of GSK-3 inhibitors in vitro, in vivo, and in different cellular lines. Mol Divers 2010;15(2):561-7
91. Haq ZU, Uddin R, Wai LK, et al. Docking and 3D-QSAR modeling of cyclin-dependent kinase 5/p25 inhibitors. J Mol Model 2011;17(5):1149-61
92. Ambure P, Roy K. Exploring structural requirements of leads for improving activity and selectivity against CDK5/ p25 in Alzheimer's disease: An in silico approach. RSC Adv 2014;4(13):6702-9
93. Efange SMN, Garland EM, Staley JK, et al. Vesicular acetylcholine transporter density and Alzheimer's disease. Neurobiol Aging 1997;18(4):407-13
94. Wang W, Zhang J, Liu B. QSAR study of 125 I-labeled 2-(4-Aminophenyl) benzothiazole derivatives as imaging agents for b-Amyloid in the brain with Alzheimer's disease. J Radioanal Nucl Chem 2005;266(1):107-11 (Pubitemid 41285557
95. Chen X. QSAR and primary docking studies of trans-stilbene (TSB) series of imaging agents for beta-Amyloid plaques. J Mol Struct 2006;763(1):83-9
96. Kim MK, Choo IH, Lee HS, et al. 3D-QSAR of PET agents for imaging beta-Amyloid in Alzheimer's disease. Bull Korean Chem Soc 2007;28(7):1231
97. Kovac M, Mavel S, Deuther-Conrad W, et al. 3D QSAR study, synthesis, and in vitro evaluation of (+)-5-FBVM as potential PET radioligand for the vesicular acetylcholine transporter (VAChT). Bioorg Med Chem 2010;18(21):7659-67
98. Yang Y, Zhu L, Chen X, Zhang H. Binding research on flavones as ligands of beta-Amyloid aggregates by fluorescence and their 3D-QSAR, docking studies. J Mol Graph Model 2010;29(4):538-45
99. Cisek K, Kuret J. QSAR studies for prediction of cross-beta sheet aggregate binding affinity and selectivity. Bioorg Med Chem 2012;20(4):1434-41
100. Lam YA, Pickart CM, Alban A, et al. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc Natl Acad Sci USA 2000;97(18):9902-6
101. Zhu Y-Q, Pei J-F, Liu Z-M, et al. 3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using CoMFA and CoMSIA methods. Bioorg Med Chem 2006;14(5):1483-96 (Pubitemid 43120285
102. Ishiura S, Tsukahara T, Tabira T, et al. Identification of a putative amyloid A4-generating enzyme as a prolyl endopeptidase. FEBS Lett 1990;260(1):131-4 (Pubitemid 20029447
103. Pripp AH. Quantitative structure-Activity relationship of prolyl oligopeptidase inhibitory peptides derived from b-casein using simple amino acid descriptors. J Agric Food Chem 2006;54(1):224-8 (Pubitemid 43119943
104. Brioni JD, Esbenshade TA, Garrison TR, et al. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J Pharmacol Exp Ther 2011;336(1):38-46
105. Dastmalchi S, Hamzeh-Mivehroud M, Ghafourian T, Hamzeiy H. Molecular modeling of histamine H3 receptor and QSAR studies on arylbenzofuran derived H3 antagonists. J Mol Graph Model 2008;26(5):834-44 (Pubitemid 350213441
106. Riederer P, Danielczyk W, Grunblatt E. Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology 2004;25(1):271-7 (Pubitemid 38044188
107. Speck-Planche A, Kleandrova VV. QSAR and molecular docking techniques for the discovery of potent monoamine oxidase B inhibitors: Computer-Aided generation of new rasagiline bioisosteres. Curr Top Med Chem 2012;12(16):1734-47
108. Firoozpour L, Sadatnezhad K, Dehghani S, et al. An efficient piecewise linear model for predicting activity of caspase-3 inhibitors. DARU J Pharm Sci 2012;20(1):31
109. Hajjo R, Setola V, Roth BL, Tropsha A. Chemocentric informatics approach to drug discovery: Identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers. J Med Chem 2012;55(12):5704-19
110. Makhaeva GF, Radchenko EV, Baskin II, et al. Combined QSAR studies of inhibitor properties of O-phosphorylated oximes toward serine esterases involved in neurotoxicity, drug metabolism and Alzheimer's disease. SAR QSAR Environ Res 2012;23(7-8):627-47
111. Fresqui MAC, Ferreira MM, Trsic M. The influence of R and S configurations of a series of amphetamine derivatives on QSAR models. Anal Chim Acta 2013;759:43-52
112. Ryoo S-R, Cho H-J, Lee H-W, et al. Dual-specificity tyrosine (Y)-phosphorylation regulated kinase 1-mediated phosphorylation of amyloid precursor protein: Evidence for a functional link between Down syndrome and Alzheimer's disease. J Neurochem 2008;104(5):1333-44 (Pubitemid 351293338
113. Bharate SB, Yadav RR, Vishwakarma RA. QSAR and pharmacophore study of Dyrk1A inhibitory meridianin analogs as potential agents for treatment of neurodegenerative diseases. Med Chem 2013;9(1):152-61
114. Nayana MRS, Sekhar YN, Kumari NS, Mahmood S. 3D-QSAR CoMFA study on human glutaminyl cyclase inhibitors. Internet Electron J Mol Des 2007;6:320-30
115. Diniz C, Borges F, Santana L, et al. Ligands and therapeutic perspectives of adenosine A2A receptors. Curr Pharm Des 2008;14(17):1698-722 (Pubitemid 351998595
116. Geldenhuys WJ, Van Der Schyf CJ. Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimers disease. Curr Top Med Chem 2008;8(12):1035-48
117. Sun A, Liu M, Nguyen XV, Bing G. P38 MAP kinase is activated at early stages in Alzheimer's disease brain. Exp Neurol 2003;183(2):394-405 (Pubitemid 37205081
118. Femminella GD, Rengo G, Pagano G, et al. Beta-Adrenergic receptors and G protein-coupled receptor kinase-2 in Alzheimer's disease: A new paradigm for prognosis and therapy? J Alzheimers Dis 2013;34(2):341-7
119. Thathiah A, Horre K, Snellinx A, et al. [beta]-Arrestin 2 regulates A [beta] generation and [gamma]-secretase activity in Alzheimer's disease. Nat med 2013;19(1):43-9
120. Tang Z, Bereczki E, Zhang H, et al. Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis implication for Alzheimer disease. J Biol Chem 2013;288(22):15556-70
121. Albani D, Polito L, Forloni G. Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: Experimental and genetic evidence. J Alzheimers Dis 2010;19(1):11-26
122. Rosen C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease-current concepts. Mol Neurodegener 2013;8:20
123. Bekris LM, Lutz F, Montine TJ, et al. MicroRNA in Alzheimer's disease: An exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers 2013;18(5):455-66
124. Podlesniy P, Figueiro-Silva J, Llado A, et al. Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Ann neurol 2013;74(5):655-68